Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3486-3496

  Kim, Seok Jin ^a   Hsu, Chiun ^b   Song, Yu Qin ^c   Tay, Kevin ^d   Hong, Xiao Nan ^e   Cao, Junning ^e   Kim, Jin Seok ^f   Eom, Hyeon Seok ^g   Lee, Joon Hyeok ^a   Zhu, Jun ^c   Chang, Kian Meng ^h   Reksodiputro, Arry Harryanto ⁱ   Tan, Daryl ^j   Goh, Yeow Tee ^j   Lee, Jejung ^k   Intragumtornchai, Tanin ^l   Chng, Wee Joo ^m   Cheng, Ann Lii ^b   Lim, Soon Thye ^d   Suh, Cheolwon ⁿ   Kwong, Yok Lam ^o   Kim, Won Seog ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^f Yonsei University College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

^h Hospital Ampang   (Malaysia)

ⁱ CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^j SINGAPORE GENERAL HOSPITAL   (Singapore)

^k Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^l CHULALONGKORN UNIVERSITY   (Thailand)

^m NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

ⁿ Asan Medical Center   (South Korea)

^o QUEEN MARY HOSPITAL   (Hong Kong)

more..

Author keywords

B cell; Hepatitis B virus; Lymphoma; Rituximab

Indexed keywords

ADEFOVIR; CLEVUDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; VINCRISTINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; B CELL LYMPHOMA; CHEMOTHERAPY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; VIRUS REACTIVATION;

B-CELL; HEPATITIS B VIRUS; LYMPHOMA; RITUXIMAB;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; ASIA; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DNA, VIRAL; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84885184821     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.006     Document Type: Article

References (34)

1. W. Yeo, P.K. Chan, and S. Zhong Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 3 2000 299 307
2. W. Yeo, B. Zee, and S. Zhong Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy Br J Cancer 90 7 2004 1306 1311
3. Y.F. Liaw Hepatitis viruses under immunosuppressive agents J Gastroenterol Hepatol 13 1 1998 14 20
4. C.H. Hsu, H.C. Hsu, and H.L. Chen Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy Anticancer Res 24 5A 2004 3035 3040
5. L.E. van der Kolk, J.W. Baars, M.H. Prins, and M.H. van Oers Rituximab treatment results in impaired secondary humoral immune responsiveness Blood 100 6 2002 2257 2259
6. J.J. Chang, and S.R. Lewin Immunopathogenesis of hepatitis B virus infection Immunol Cell Biol 85 1 2007 16 23
7. A.M. Evens, B.D. Jovanovic, and Y.C. Su Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports Ann Oncol 22 5 2011 1170 1180
8. W. Yeo, P.K. Chan, and W.M. Ho Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy J Clin Oncol 22 5 2004 927 934
9. G.K. Lau, H.H. Yiu, and D.Y. Fong Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 6 2003 1742 1749
10. R. Loomba, A. Rowley, and R. Wesley Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 7 2008 519 528
11. P.D. Ziakas, P. Karsaliakos, and E. Mylonakis Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance Haematologica 94 7 2009 998 1005
12. J.K. Law, J.A. Ali, P.R. Harrigan, C.H. Sherlock, K.J. Savage, and E.M. Yoshida Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient Am J Hematol 81 12 2006 969 972
13. W. Yeo, T.C. Chan, and N.W. Leung Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 4 2009 605 611
14. C.K. Hui, W.W. Cheung, and H.Y. Zhang Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 1 2006 59 68
15. Y.X. Koo, M. Tay, and Y.E. Teh Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis Ann Hematol 90 10 2011 1219 1223
16. L.C. Park, S.Y. Woo, and S. Kim Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population Thromb Res 130 3 2012 e6 12
17. H.A. Jung, S. Park, and J.H. Cho Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study Ann Hematol 91 11 2012 1747 1756
18. Y.F. He, Y.H. Li, and F.H. Wang The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma Ann Hematol 87 6 2008 481 485
19. S.N. Pei, C.H. Chen, and C.M. Lee Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients Ann Hematol 89 3 2010 255 262
20. Y. Tsutsumi, A. Shigematsu, and S. Hashino Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido Ann Hematol 88 4 2009 375 377
21. H.R. Li, J.J. Huang, and H.Q. Guo Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy J Viral Hepat 18 12 2011 877 883
22. M. Sherman, C. Yurdaydin, and J. Sollano Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 130 7 2006 2039 2049
23. C.K. Hui, W.W. Cheung, and W.Y. Au Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy Gut 54 11 2005 1597 1603
24. C.M. Mastroianni, M. Lichtner, and R. Citton Current trends in management of hepatitis B virus reactivation in the biologic therapy era World J Gastroenterol 17 34 2011 3881 3887
25. H.A. Torres, and M. Davila Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer Nat Rev Clin Oncol 9 3 2012 156 166
26. M. Oketani, A. Ido, H. Uto, and H. Tsubouchi Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy Hepatol Res 42 7 2012 627 636
27. C. Targhetta, M.G. Cabras, A.M. Mamusa, G. Mascia, and E. Angelucci Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy Haematologica 93 6 2008 951 952
28. K. Matsue, S. Kimura, and Y. Takanashi Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma Cancer 116 20 2010 4769 4776
29. D. Ji, J. Cao, and X. Hong Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study Eur J Haematol 85 3 2010 243 250
30. S.N. Pei, M.C. Ma, and M.C. Wang Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy Ann Hematol 91 7 2012 1007 1012
31. N. Fukushima, T. Mizuta, and M. Tanaka Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier Ann Oncol 20 12 2009 2013 2017
32. S. Kusumoto, Y. Tanaka, M. Mizokami, and R. Ueda Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma Int J Hematol 90 1 2009 13 23
33. C. Hsu, H.H. Tsou, and S.J. Lin Incidence of hepatitis B (HBV) reactivations in non-Hodgkin's lymphoma patients with resolved HBV infections and received rituximab-containing chemotherapy Hepatology Int 6 2012 65
34. S. Kusumoto, Y. Tanaka, and R. Suzuki Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B-cell non-Hodgkin Lymphoma following rituximab containing chemotherapy: results of interim analysis Blood 120 21 2012 2641